MIMEDX GROUP INC (MDXG)
US6024961012 - Common Stock
We assign a fundamental rating of 6 out of 10 to MDXG. MDXG was compared to 565 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
In the past 5 years MDXG reported 4 times negative net income.
MDXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
MDXG has a Return On Assets of 33.62%. This is amongst the best in the industry. MDXG outperforms 99.11% of its industry peers.
With an excellent Return On Equity value of 45.30%, MDXG belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
MDXG has a better Return On Invested Capital (24.79%) than 99.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 33.62% | ||
| ROE | 45.3% | ||
| ROIC | 24.79% |
ROA(3y)-3.57%
ROA(5y)-13.45%
ROE(3y)-11.49%
ROE(5y)-40%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a Profit Margin of 23.92%. This is amongst the best in the industry. MDXG outperforms 97.69% of its industry peers.
MDXG's Operating Margin of 18.49% is amongst the best of the industry. MDXG outperforms 96.09% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
MDXG has a better Gross Margin (83.37%) than 87.90% of its industry peers.
MDXG's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.49% | ||
| PM (TTM) | 23.92% | ||
| GM | 83.37% |
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
The number of shares outstanding for MDXG has been increased compared to 1 year ago.
MDXG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 15.10. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
MDXG has a better Altman-Z score (15.10) than 90.04% of its industry peers.
The Debt to FCF ratio of MDXG is 0.34, which is an excellent value as it means it would take MDXG, only 0.34 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.34, MDXG belongs to the best of the industry, outperforming 96.98% of the companies in the same industry.
MDXG has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
MDXG has a worse Debt to Equity ratio (0.10) than 65.30% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 15.1 |
ROIC/WACC2.24
WACC11.05%
2.3 Liquidity
MDXG has a Current Ratio of 4.10. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio (4.10) which is in line with its industry peers.
MDXG has a Quick Ratio of 3.53. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDXG (3.53) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.53 |
3. Growth
3.1 Past
MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2900.00%, which is quite impressive.
The Revenue has grown by 10.93% in the past year. This is quite good.
Measured over the past years, MDXG shows a decrease in Revenue. The Revenue has been decreasing by -2.19% on average per year.
EPS 1Y (TTM)2900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)10.93%
Revenue growth 3Y9.01%
Revenue growth 5Y-2.19%
Sales Q2Q%2.87%
3.2 Future
Based on estimates for the next years, MDXG will show a very strong growth in Earnings Per Share. The EPS will grow by 38.07% on average per year.
The Revenue is expected to grow by 11.61% on average over the next years. This is quite good.
EPS Next Y-3.58%
EPS Next 2Y-0.6%
EPS Next 3Y11.51%
EPS Next 5Y38.07%
Revenue Next Year7.98%
Revenue Next 2Y8.58%
Revenue Next 3Y10.13%
Revenue Next 5Y11.61%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.36 indicates a correct valuation of MDXG.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 96.26% of the companies are valued more expensively.
MDXG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.20.
The Price/Forward Earnings ratio is 28.97, which means the current valuation is very expensive for MDXG.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 93.59% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.73. MDXG is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 28.97 |
4.2 Price Multiples
95.73% of the companies in the same industry are more expensive than MDXG, based on the Enterprise Value to EBITDA ratio.
95.55% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.15 | ||
| EV/EBITDA | 18.85 |
4.3 Compensation for Growth
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.6%
EPS Next 3Y11.51%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIMEDX GROUP INC
NASDAQ:MDXG (12/23/2024, 11:29:07 AM)
9.16
+0.06 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.09%
Inst Owner Change4.48%
Ins Owners2.13%
Ins Owner Change0.22%
Market Cap1.35B
Analysts81.82
Price Target12.85 (40.28%)
Short Float %2.39%
Short Ratio4.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.96%
Min EPS beat(2)11.41%
Max EPS beat(2)52.51%
EPS beat(4)4
Avg EPS beat(4)116.15%
Min EPS beat(4)11.41%
Max EPS beat(4)348.18%
EPS beat(8)8
Avg EPS beat(8)84.25%
EPS beat(12)9
Avg EPS beat(12)57.62%
EPS beat(16)12
Avg EPS beat(16)38.91%
Revenue beat(2)0
Avg Revenue beat(2)-2.1%
Min Revenue beat(2)-3.85%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)0.13%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)4.65%
Revenue beat(8)5
Avg Revenue beat(8)2.15%
Revenue beat(12)8
Avg Revenue beat(12)2.32%
Revenue beat(16)11
Avg Revenue beat(16)3.17%
PT rev (1m)3.28%
PT rev (3m)2.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.49%
EPS NY rev (1m)1.51%
EPS NY rev (3m)12.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 28.97 | ||
| P/S | 3.93 | ||
| P/FCF | 24.15 | ||
| P/OCF | 23.34 | ||
| P/B | 7.44 | ||
| P/tB | 8.95 | ||
| EV/EBITDA | 18.85 |
EPS(TTM)0.56
EY6.11%
EPS(NY)0.32
Fwd EY3.45%
FCF(TTM)0.38
FCFY4.14%
OCF(TTM)0.39
OCFY4.28%
SpS2.33
BVpS1.23
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 33.62% | ||
| ROE | 45.3% | ||
| ROCE | 31.38% | ||
| ROIC | 24.79% | ||
| ROICexc | 44.25% | ||
| ROICexgc | 60.68% | ||
| OM | 18.49% | ||
| PM (TTM) | 23.92% | ||
| GM | 83.37% | ||
| FCFM | 16.26% |
ROA(3y)-3.57%
ROA(5y)-13.45%
ROE(3y)-11.49%
ROE(5y)-40%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-12.01%
ROICexcg growth 5YN/A
ROICexc growth 3Y5.84%
ROICexc growth 5Y-45.11%
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
F-Score7
Asset Turnover1.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.34 | ||
| Debt/EBITDA | 0.27 | ||
| Cap/Depr | 50.16% | ||
| Cap/Sales | 0.56% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.78% | ||
| Profit Quality | 67.97% | ||
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.53 | ||
| Altman-Z | 15.1 |
F-Score7
WACC11.05%
ROIC/WACC2.24
Cap/Depr(3y)65.35%
Cap/Depr(5y)58.37%
Cap/Sales(3y)1%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-3.58%
EPS Next 2Y-0.6%
EPS Next 3Y11.51%
EPS Next 5Y38.07%
Revenue 1Y (TTM)10.93%
Revenue growth 3Y9.01%
Revenue growth 5Y-2.19%
Sales Q2Q%2.87%
Revenue Next Year7.98%
Revenue Next 2Y8.58%
Revenue Next 3Y10.13%
Revenue Next 5Y11.61%
EBIT growth 1Y177.7%
EBIT growth 3Y40.96%
EBIT growth 5Y-2.25%
EBIT Next Year226.71%
EBIT Next 3Y63.14%
EBIT Next 5Y48.92%
FCF growth 1Y431.96%
FCF growth 3YN/A
FCF growth 5Y-0.91%
OCF growth 1Y472.07%
OCF growth 3YN/A
OCF growth 5Y-5.64%